EE513 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Large B-Cell Lymphoma—Exploring the Impact of Country Settings and Performance-Based Managed Entry Agreements
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.778
https://www.valueinhealthjournal.com/article/S1098-3015(23)03908-6/fulltext
Title :
EE513 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Large B-Cell Lymphoma—Exploring the Impact of Country Settings and Performance-Based Managed Entry Agreements
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03908-6&doi=10.1016/j.jval.2023.09.778
First page :
Section Title :
Open access? :
No
Section Order :
10265